HPS2THRIVE analysis Adding niacin with laropiprant to statin reduced survival...
Quality of lifeadjusted survival was reduced and hospital costs rose due to the addition of extendedrelease niacin with laropiprant to statinbased therapy according to a new analysis of the HPS2THRIVE...
View ArticleSingulex Cardiac Troponin Test Predicts Cardiac Risk In Stable Patients
Results of from a new analysis of plasma samples from an old statin trial suggest that Singulex highsensitivity cardiac troponin...&160;&160;&160;
View ArticleResearch Study Reveals Black Consumer Attitudes on Treatment For Cholesterol
NEW YORK Aug. 1 2016 PRNewswire &160;The Association of Black Cardiologists ABC conducted a primary research study designed to investigate attitudes among Black consumers regarding their use of...
View ArticleMedical Education Company releases 6th Annual Primary Care Fall CME...
Continuing Education Company Inc. releases 2016 6th Annual Primary Care Fall CME Conference agenda being held October 1721 2016 at the Sheraton Maui Resort & Spa. Conference is specifically for...
View ArticleStudy Pharmacist intervention improves statin therapy in minority populations
Michael JohnsenPrevious research has shown that the lower adherence to cardiovascular medications among AfricanAmerican and Hispanic patients likely contributes to a persistent 7year lower overall life...
View ArticleStudy sheds light on cholesterol and diabetes link
A slight increase in risk of developing type 2 diabetes during statin treatment may be a consequence of having lowered cholesterol rather than a direct effect of the drug according to UK researchers.
View ArticleAmarin and FDA Reaffirm Concurrence on REDUCEIT Through Special Protocol...
BEDMINSTER NJ and DUBLIN IRELANDMarketwired August 04 2016 Amarin Corporation plc NASDAQ AMRN today announced that the U.S. Food and Drug Administration FDA agreed to an amendment of the company's...
View ArticleAmerican pharmacy adds 35 products to list of excluded drugs
American pharmacy chain CVS Health has added 35 products to its list of excluded drugs and will not cover certain diabetes and cancer treatments in an attempt to tackle hyperinflationary drugs and...
View ArticleOlympians among the latest to hawk unproven and potentially unsafe dietary...
As reported last week by the Boston Globes Stat News 14 Olympic sports federations including USA Gymnastics and USA Track & Field have signed sponsorship deals with dietary supplement...
View ArticleAmarin Omeros fall after followons
Shares of Amarin Corp. plc NASDAQAMRN and Omeros Corp. NASDAQOMER both slipped on Thursday after the companies priced followons. Amarin raised $60.1 million through the sale of 21.1 million ADSs at...
View ArticleNovel lipid altering therapies will steer acute coronary syndrome market...
The acute coronary syndrome ACS market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022 at a relatively strong compound annual growth rate of 4.6. The launch of several new lipid...
View ArticleAmarin closes $65mm public ADS sale
Amarin Corp. PLC cardiovascular therapeutics netted $65mm through the public sale of 24.27mm American Depositary Shares representing 24.27mm common shares; total includes exercise of the overallotment...
View ArticleCosteffectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD
This study estimates the costeffectiveness of adding proprotein convertase subtilisinkexin type 9 PCSK9 inhibitors to statin therapy for patients with heterozygous familial hypercholesterolemia FH or...
View ArticleStatin APIs from Gedeon Richterlinked firm should be prohibited say GMP...
German regulators want statin APIs made by Artemis Biotech to be banned after finding deviations good manufacturing practice GMP at the firms facility in Hyderabad India.
View ArticleBen Goldacre Attacks Big Pharma For Causing Panic And Anxiety Over Lack Of...
Statins have probably been studied in more people than any other class of drugs and have proven to be a major weapon in fighting heart disease. Dr. Goldacre really doesnt need to be anxious about their...
View ArticleBig Pharma Isn't Lacking In Statin Studies
Statins have probably been studied in more people than any other class of drugs and have proven to be a major weapon in fighting heart disease. Dr. Goldacre really doesnt need to be anxious about their...
View ArticlePCSK9 inhibitors Reducing annual drug prices from more than $14000 to $4536...
PCSK9 inhibitorsÂReducing annual drug prices from more than $14000 to $4536 would be necessary to meet a $100000 per QALY threshold per JAMA Curator Aviva LevAri PhD RN &160; Our team has...
View ArticleJournal of the American College of Cardiology JACC Publishes Data Assessing...
BARCELONA Spain Aug. 18 2016 PRNewswire &160;Ferrer a privatelyheld pharmaceutical company based in Barcelona today announced the online publication of findings from the companysponsored MINERVA...
View ArticleArefa MD's Morning Report StatinSSRI Combination Statins in CKD Warfarin...
Dr Arefa Cassoobhoy provides a quick rundown of this week's news on statins to augment SSRIs statins in CKD warfarin and INR stability and exercise as prevention. Medscape Internal Medicine
View Article